Abstract
A multicentre single-arm study testing the efficacy and toxicity of the oral combination of fludarabine and cyclophosphamide (FC) over 5 d in 75 patients with untreated B cell-chronic lymphocytic leukaemia. Oral FC demonstrated high efficacy with overall (OR) and complete response (CR) rates of 80% and 53%, respectively. Out of the 30 CR patients studied for Minimal Residual Disease (MRD) using 4-colour flow-cytometry and the 22 using Clonospecific polymerase chain reaction, 22 (66%) and 16 (68%), respectively, were MRD negative. Median survival and median treatment-free interval had not been reached at 7 years of follow-up. Median progression-free survival (PFS) was 5 years. Toxicity was acceptable, with 52% and 16% of National Cancer Institute grade 3/4 neutropenia and infections, respectively. Gastrointestinal toxicity was mild. Oral FC demonstrated a high efficacy and an acceptable safety profile and may be considered as the standard first line treatment in chronic lymphocytic leukaemia.
References
Aug 1, 1990·Statistics in Medicine·E BellissantC Chastang
Apr 8, 1999·Hematology and Cell Therapy·C MagnacK Maloum
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A MorrisonC A Schiffer
Oct 6, 2001·Blood·M LeporrierUNKNOWN French Cooperative Group on Chronic Lymphocytic Leukemia
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A BoogaertsM Klein
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·D OscierH Gieschen
May 3, 2002·Blood·Michael J KeatingKanti R Rai
Dec 11, 2002·British Journal of Haematology·Karim MaloumHélène Merle-Béral
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J-F RossiS M Tollerfield
Apr 9, 2004·Leukemia·C-M WendtnerUNKNOWN German CLL Study Group (GCLLSG)
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas ElterAndreas Engert
Oct 13, 2005·Blood·Barbara F EichhorstUNKNOWN German CLL Study Group
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdNyla A Heerema
Apr 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco MontilloEnrica Morra
Jun 6, 2006·The Lancet Oncology·Asher Chanan-Khan, Carl W Porter
Nov 7, 2006·British Journal of Haematology·Barbara F EichhorstUNKNOWN German CLL Study Group (GCLLSG)
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Mar 8, 2007·British Journal of Haematology·Gautam BorthakurMichael J Keating
Jun 2, 2007·Blood·Lan LinTomas Ganz
Citations
Jul 1, 2008·Annals of Hematology·Luca LaurentiGiuseppe Leone
Apr 3, 2009·Annals of Hematology·Karim MaloumHélène Merle-Béral
Feb 18, 2012·Blood·Stephane LepretrePierre Feugier
May 18, 2013·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
May 14, 2009·Therapeutics and Clinical Risk Management·Francesca RicciMarco Montillo
Oct 16, 2012·Haematologica·Emmanuelle BouvetLoic Ysebaert
Jul 14, 2010·Annals of Hematology·Luca LaurentiGiuseppe Leone
Jun 18, 2014·Leukemia Research·Alessandro GozzettiMonica Bocchia
Jan 8, 2010·Drug Design, Development and Therapy·Ann JanssensGregor Verhoef
Jul 4, 2015·Leukemia & Lymphoma·Caroline DartigeasVéronique Leblond
Sep 3, 2011·Leukemia Research·Francesca Romana MauroUNKNOWN Gruppo Italiano Trapianto di Midollo Osseo
Jun 1, 2011·Cancer·Claire E DeardenPeter Hillmen
Apr 17, 2014·Blood·Christian H GeislerMarinus H J van Oers
Aug 12, 2006·Mayo Clinic Proceedings·Karen W L Yee, Susan M O'Brien
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Sep 13, 2017·Expert Opinion on Biological Therapy·Rabih Said, Apostolia M Tsimberidou